KUALA LUMPUR (Sept 28): Bintai Kinden Corp Bhd said it today entered into a memorandum of understanding (MOU) with Institut Jantung Negara Sdn Bhd (IJN) to explore a possible collaboration in the commercial development of Covid-19 vaccine in Malaysia based on an existing partnership between Bintai Kinden and US-based Generex Biotechnology Corp.

In a statement to Bursa Malaysia today, Bintai Kinden said it is partnering Generex to commercialise the Ii-Key-SARS-CoV-2 coronavirus vaccine in Malaysia.

IJN is also known as the National Heart Institute, which specialises in cardiovascular and thoracic medicine, according to its website.